| 1 | Encased Heart – A Very Rare Post Myocardial Infarction Complication Sequela | 0.0 | 0 | Citations (PDF) |
| 2 | Long‐term follow‐up of web‐based and group‐based behavioural intervention in <scp>NAFLD</scp> in a real world clinical setting | 3.9 | 10 | Citations (PDF) |
| 3 | Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus | 4.5 | 4 | Citations (PDF) |
| 4 | Metformin and the Liver: Unlocking the Full Therapeutic Potential | 3.5 | 28 | Citations (PDF) |
| 5 | Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over? | 2.4 | 7 | Citations (PDF) |
| 6 | Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database | 21.2 | 138 | Citations (PDF) |
| 7 | The treatment of diabetes in advanced liver disease: change of a paradigm | 1.6 | 5 | Citations (PDF) |
| 8 | Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent | 3.4 | 19 | Citations (PDF) |
| 9 | Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs | 4.7 | 11 | Citations (PDF) |
| 10 | Impact of migration on diabetes burden: audit in the metropolitan area of Bologna, Italy | 3.0 | 3 | Citations (PDF) |
| 11 | Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM | 6.2 | 24 | Citations (PDF) |
| 12 | Risk of binge eating disorder in patients with metabolic dysfunction-associated steatotic liver disease | 2.4 | 7 | Citations (PDF) |
| 13 | The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention | 4.3 | 14 | Citations (PDF) |
| 14 | The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality | 52.8 | 547 | Citations (PDF) |
| 15 | Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) | 3.4 | 24 | Citations (PDF) |
| 16 | Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) | 2.4 | 28 | Citations (PDF) |
| 17 | The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? | 3.6 | 219 | Citations (PDF) |
| 18 | A psycho-educational intervention for the prevention of foot lesions in people with diabetes: Report of a clinical audit | 3.4 | 4 | Citations (PDF) |
| 19 | Non-alcoholic fatty liver disease: Not time for an obituary just yet! | 3.6 | 30 | Citations (PDF) |
| 20 | Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis | 4.1 | 40 | Citations (PDF) |
| 21 | European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease? | 4.8 | 36 | Citations (PDF) |
| 22 | Incidence of diabetes mellitus in Italy in year 2018. A nationwide population-based study of the ARNO Diabetes Observatory | 3.4 | 16 | Citations (PDF) |
| 23 | Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges | 4.7 | 82 | Citations (PDF) |
| 24 | Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory | 3.4 | 8 | Citations (PDF) |
| 25 | The Effect of Neuropathy and Diabetes Type on Multisegment Foot Kinematics: A Cohort Study on 70 Participants with Diabetes | 2.2 | 2 | Citations (PDF) |
| 26 | Non-alcoholic fatty liver disease: A patient guideline | 4.8 | 189 | Citations (PDF) |
| 27 | Advancing the global public health agenda for NAFLD: a consensus statement | 48.0 | 608 | Citations (PDF) |
| 28 | Analysis of Clinical Profiles, Deformities, and Plantar Pressure Patterns in Diabetic Foot Syndrome | 2.2 | 2 | Citations (PDF) |
| 29 | Prognostic Value of Stress Hyperglycemia in Patients Admitted to Medical/Geriatric Departments for Acute Medical Illness | 2.1 | 5 | Citations (PDF) |
| 30 | Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease | 6.2 | 144 | Citations (PDF) |
| 31 | A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe | 3.6 | 155 | Citations (PDF) |
| 32 | Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation | 10.6 | 273 | Citations (PDF) |
| 33 | A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory | 3.4 | 20 | Citations (PDF) |
| 34 | Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis 2020, 2, e0152 | | 45 | Citations (PDF) |
| 35 | Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory | 3.6 | 23 | Citations (PDF) |
| 36 | Correlations between weight‐bearing 3D bone architecture and dynamic plantar pressure measurements in the diabetic foot | 2.0 | 15 | Citations (PDF) |
| 37 | Motivational Interviewing Adapted to Group Setting for the Treatment of Relapse in the Behavioral Therapy of Obesity. A Clinical Audit | 4.7 | 9 | Citations (PDF) |
| 38 | Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background | 3.4 | 9 | Citations (PDF) |
| 39 | Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders | 2.4 | 11 | Citations (PDF) |
| 40 | Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy | 3.4 | 34 | Citations (PDF) |
| 41 | Nurse-managed basal-bolus versus sliding-scale insulin regimen in subjects with hyperglycemia at admission for orthopedic surgery: a propensity score approach | 2.4 | 14 | Citations (PDF) |
| 42 | Fatty liver in pregnancy: a narrative review of two distinct conditions | 2.5 | 29 | Citations (PDF) |
| 43 | <p>Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery</p> | 2.7 | 40 | Citations (PDF) |
| 44 | Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update | 2.4 | 11 | Citations (PDF) |
| 45 | Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations | 3.4 | 26 | Citations (PDF) |
| 46 | Combination of GLP‐1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study | 2.6 | 13 | Citations (PDF) |
| 47 | Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes | 2.6 | 23 | Citations (PDF) |
| 48 | Prevention and Treatment of Sarcopenic Obesity in Women | 4.7 | 74 | Citations (PDF) |
| 49 | Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution | 0.2 | 10 | Citations (PDF) |
| 50 | Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? | 2.2 | 4 | Citations (PDF) |
| 51 | Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink? | 4.7 | 37 | Citations (PDF) |
| 52 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial | 52.8 | 1,092 | Citations (PDF) |
| 53 | Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) | 2.4 | 99 | Citations (PDF) |
| 54 | Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients | 2.9 | 20 | Citations (PDF) |
| 55 | Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system | 2.4 | 25 | Citations (PDF) |
| 56 | Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution | 2.4 | 4 | Citations (PDF) |
| 57 | Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases | 9.6 | 43 | Citations (PDF) |
| 58 | Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity | 2.4 | 18 | Citations (PDF) |
| 59 | The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System | 2.1 | 11 | Citations (PDF) |
| 60 | DXA-assessed changes in body composition in obese women following two different weight loss programs | 2.9 | 10 | Citations (PDF) |
| 61 | Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis | 10.6 | 377 | Citations (PDF) |
| 62 | Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis | 10.6 | 313 | Citations (PDF) |
| 63 | The Effect of Lutein on Eye and Extra-Eye Health | 4.7 | 215 | Citations (PDF) |
| 64 | An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers | 3.6 | 110 | Citations (PDF) |
| 65 | Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease | 2.2 | 24 | Citations (PDF) |
| 66 | Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough? | 4.7 | 20 | Citations (PDF) |
| 67 | Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study | 9.9 | 66 | Citations (PDF) |
| 68 | Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 | 3.6 | 1,708 | Citations (PDF) |
| 69 | Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice | 3.0 | 3 | Citations (PDF) |
| 70 | Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis | 2.4 | 19 | Citations (PDF) |
| 71 | The association between weight maintenance and session-by-session diet adherence, weight loss and weight-loss satisfaction | 2.4 | 20 | Citations (PDF) |
| 72 | AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions | 2.4 | 277 | Citations (PDF) |
| 73 | 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial | 52.8 | 709 | Citations (PDF) |
| 74 | Acute Heart Failure in the Emergency Department: the SAFE-SIMEU Epidemiological Study | 0.8 | 2 | Citations (PDF) |
| 75 | Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment | 4.7 | 20 | Citations (PDF) |
| 76 | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? | 2.4 | 43 | Citations (PDF) |
| 77 | Long-term treatment of severe obesity: are lifestyle interventions still an option? | 3.1 | 19 | Citations (PDF) |
| 78 | Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems | 3.4 | 42 | Citations (PDF) |
| 79 | The Influence of Weight-Loss Expectations on Weight Loss and of Weight-Loss Satisfaction on Weight Maintenance in Severe Obesity | 1.6 | 33 | Citations (PDF) |
| 80 | Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database | 2.1 | 3 | Citations (PDF) |
| 81 | Evidence-Based Medicine and the Problem of Healthy Volunteers | 1.6 | 11 | Citations (PDF) |
| 82 | Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control | 3.0 | 17 | Citations (PDF) |
| 83 | Long-term weight loss maintenance for obesity: a multidisciplinary approach | 2.7 | 197 | Citations (PDF) |
| 84 | The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease | 1.3 | 60 | Citations (PDF) |
| 85 | The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory | 3.4 | 48 | Citations (PDF) |
| 86 | Response to letter to the editor: Gallo F et al., “The economic burden of severe hypoglycemia: Two sides of the same coin” Nutr Metab Cardiovasc Dis. 2016;26:850–851. | 3.4 | 0 | Citations (PDF) |
| 87 | Costs associated with emergency care and hospitalization for severe hypoglycemia | 3.4 | 52 | Citations (PDF) |
| 88 | Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System | 3.4 | 31 | Citations (PDF) |
| 89 | Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? | 3.6 | 84 | Citations (PDF) |
| 90 | NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders | 0.7 | 3 | Citations (PDF) |
| 91 | Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0–29 years: The population-based CINECA-SID ARNO Observatory, 2002–2012 | 3.4 | 14 | Citations (PDF) |
| 92 | Switching among Equivalents in Chronic Cardiovascular Therapies: ‘Real World’ Data from Italy | 2.9 | 1 | Citations (PDF) |
| 93 | Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice | 10.6 | 279 | Citations (PDF) |
| 94 | Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women | 0.5 | 22 | Citations (PDF) |
| 95 | Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD? | 3.6 | 32 | Citations (PDF) |
| 96 | Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program | 3.2 | 13 | Citations (PDF) |
| 97 | Evidence of a diurnal thermogenic handicap in obesity | 2.0 | 19 | Citations (PDF) |
| 98 | The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients | 4.2 | 28 | Citations (PDF) |
| 99 | Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome | 2.4 | 611 | Citations (PDF) |
| 100 | Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease | 3.6 | 183 | Citations (PDF) |
| 101 | Acute heart failure in the emergency department: a follow-up study | 3.2 | 7 | Citations (PDF) |
| 102 | Aminotransferase and gamma-glutamyl transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome | 3.0 | 72 | Citations (PDF) |
| 103 | An empowerment-based educational program improves psychological well-being and health-related quality of life in Type 1 diabetes | 3.0 | 17 | Citations (PDF) |
| 104 | Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica | 0.0 | 0 | Citations (PDF) |
| 105 | Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome | 3.0 | 54 | Citations (PDF) |
| 106 | Impatto delle incretine sulla gestione del paziente diabetico: dati del monitoraggio antidiabetici AIFA | 0.0 | 0 | Citations (PDF) |
| 107 | Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? | 4.8 | 30 | Citations (PDF) |
| 108 | Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry | 3.4 | 42 | Citations (PDF) |
| 109 | Sexuality and Psychopathological Aspects in Premenopausal Women with Metabolic Syndrome | 0.5 | 26 | Citations (PDF) |
| 110 | A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry | 2.9 | 57 | Citations (PDF) |
| 111 | The Role of Medications for the Management of Patients with NAFLD | 3.7 | 28 | Citations (PDF) |
| 112 | Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes | 2.4 | 39 | Citations (PDF) |
| 113 | The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study | 3.8 | 43 | Citations (PDF) |
| 114 | A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity | 3.7 | 30 | Citations (PDF) |
| 115 | Liver in the analysis of body composition by dual-energy X-ray absorptiometry | 2.5 | 7 | Citations (PDF) |
| 116 | Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool | 5.6 | 13 | Citations (PDF) |
| 117 | Under-treatment of migrants with diabetes in a universalistic health care system: The ARNO Observatory | 3.4 | 30 | Citations (PDF) |
| 118 | Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology | 1.6 | 125 | Citations (PDF) |
| 119 | Visceral Fat and Body Composition Changes in a Female Population After RYGBP: a Two-Year Follow-Up by DXA | 2.4 | 53 | Citations (PDF) |
| 120 | Obesity in the Context of Aging: Quality of Life Considerations | 3.7 | 38 | Citations (PDF) |
| 121 | Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease | 2.4 | 129 | Citations (PDF) |
| 122 | Eating behavior affects quality of life in type 2 diabetes mellitus | 2.4 | 21 | Citations (PDF) |
| 123 | Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones | 2.9 | 36 | Citations (PDF) |
| 124 | Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH | 4.5 | 9 | Citations (PDF) |
| 125 | Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients | 3.6 | 35 | Citations (PDF) |
| 126 | Personality features of obese women in relation to binge eating and night eating | 3.3 | 34 | Citations (PDF) |
| 127 | Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease | 3.6 | 82 | Citations (PDF) |
| 128 | Emotionally focused group therapy and dietary counseling in binge eating disorder. Effect on eating disorder psychopathology and quality of life | 2.9 | 26 | Citations (PDF) |
| 129 | Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials | 3.0 | 105 | Citations (PDF) |
| 130 | Health and ageing: A cross-sectional study of body composition | 5.6 | 76 | Citations (PDF) |
| 131 | Physical activity for the prevention and treatment of metabolic disorders | 3.2 | 53 | Citations (PDF) |
| 132 | Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study | 4.2 | 109 | Citations (PDF) |
| 133 | Longstanding underweight eating disorder: Associated features and treatment outcome | 3.0 | 16 | Citations (PDF) |
| 134 | Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes | 1.1 | 48 | Citations (PDF) |
| 135 | Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study | 2.1 | 26 | Citations (PDF) |
| 136 | A randomized trial of energy‐restricted high‐protein versus high‐carbohydrate, low‐fat diet in morbid obesity | 4.2 | 57 | Citations (PDF) |
| 137 | Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study | 7.8 | 66 | Citations (PDF) |
| 138 | Major factors for facilitating change in behavioral strategies to reduce obesity | 2.9 | 67 | Citations (PDF) |
| 139 | PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease | 2.4 | 70 | Citations (PDF) |
| 140 | Personality Traits in Obesity Associated with Binge Eating and/or Night Eating | 9.7 | 10 | Citations (PDF) |
| 141 | Hepatic Encephalopathy and Health-Related Quality of Life | 3.7 | 30 | Citations (PDF) |
| 142 | Author's reply: Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome | 2.2 | 0 | Citations (PDF) |
| 143 | Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin | 1.7 | 4 | Citations (PDF) |
| 144 | Pathogenetic Mechanisms and Cardiovascular Risk | 6.5 | 38 | Citations (PDF) |
| 145 | Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations | 10.6 | 117 | Citations (PDF) |
| 146 | Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia | 10.6 | 19 | Citations (PDF) |
| 147 | Prevalence of Sexual Dysfunction Among Postmenopausal Women with and Without Metabolic Syndrome | 0.5 | 66 | Citations (PDF) |
| 148 | Objective and subjective binge eating in underweight eating disorders: Associated features and treatment outcome | 4.1 | 21 | Citations (PDF) |
| 149 | Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? | 3.0 | 90 | Citations (PDF) |
| 150 | Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease | 2.4 | 64 | Citations (PDF) |
| 151 | Night eating syndrome and weight loss outcome in obese patients | 4.1 | 28 | Citations (PDF) |
| 152 | Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome | 2.2 | 20 | Citations (PDF) |
| 153 | Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease | 2.4 | 15 | Citations (PDF) |
| 154 | High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis | 2.4 | 29 | Citations (PDF) |
| 155 | Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity | 3.6 | 112 | Citations (PDF) |
| 156 | The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory | 3.4 | 36 | Citations (PDF) |
| 157 | Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study | 3.4 | 18 | Citations (PDF) |
| 158 | Cognitive-Behavioral Strategies to Increase the Adherence to Exercise in the Management of Obesity | 3.8 | 169 | Citations (PDF) |
| 159 | Cognitive‐Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Score‐Adjusted Observational Study | 4.2 | 48 | Citations (PDF) |
| 160 | Effects of Cognitive-Behavioral Treatment for Weight Loss in Family Members | 1.5 | 27 | Citations (PDF) |
| 161 | HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas | 2.4 | 24 | Citations (PDF) |
| 162 | Therapeutic hypothermia after cardiac arrest: The Mediterranean-diet Italian style | 2.8 | 1 | Citations (PDF) |
| 163 | Analysis of Different Decision Aids for Clinical Use in Pediatric Head Injury in an Emergency Department of a General Hospital | 2.2 | 6 | Citations (PDF) |
| 164 | Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study | 0.5 | 71 | Citations (PDF) |
| 165 | Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C | 21.2 | 33 | Citations (PDF) |
| 166 | The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database | 2.4 | 107 | Citations (PDF) |
| 167 | A psychological support program for individuals with Type 1 diabetes | 2.4 | 21 | Citations (PDF) |
| 168 | Effects of cognitive-behavioral therapy on Eating Disorders: Neurotransmitter secretory response to treatment | 2.8 | 11 | Citations (PDF) |
| 169 | The changing face of mild head injury: Temporal trends and patterns in adolescents and adults from 1997 to 2008 | 1.8 | 17 | Citations (PDF) |
| 170 | Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C | 10.6 | 393 | Citations (PDF) |
| 171 | Clinical and psychological correlates of health-related quality of life in obese patients | 3.0 | 75 | Citations (PDF) |
| 172 | Lifestyle modification in the management of the metabolic syndrome: achievements and challenges | 2.7 | 69 | Citations (PDF) |
| 173 | Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury | 7.3 | 38 | Citations (PDF) |
| 174 | Double Heterozygous Mutations Involving Both <i>HNF1A</i>/MODY3 and <i>HNF4A</i>/MODY1 Genes | 6.5 | 22 | Citations (PDF) |
| 175 | Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease | 21.2 | 166 | Citations (PDF) |
| 176 | Insulin Resistance in Nonalcoholic Fatty Liver Disease | 2.4 | 367 | Citations (PDF) |
| 177 | Prevention and treatment of nonalcoholic fatty liver disease | 2.4 | 18 | Citations (PDF) |
| 178 | HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease | 1.0 | 262 | Citations (PDF) |
| 179 | A position statement on NAFLD/NASH based on the EASL 2009 special conference | 3.6 | 963 | Citations (PDF) |
| 180 | Weight management, psychological distress and binge eating in obesity. A reappraisal of the problem | 2.9 | 36 | Citations (PDF) |
| 181 | Lifestyle modification in the management of the metabolic syndrome: achievements and challenges | 2.7 | 73 | Citations (PDF) |
| 182 | Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis | 4.8 | 42 | Citations (PDF) |
| 183 | ESPEN Guidelines on Parenteral Nutrition: Hepatology | 5.6 | 231 | Citations (PDF) |
| 184 | Psychological Variables Associated with Weight Loss in Obese Patients Seeking Treatment at Medical Centers | 1.5 | 74 | Citations (PDF) |
| 185 | Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis | 10.6 | 66 | Citations (PDF) |
| 186 | Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C | 10.6 | 143 | Citations (PDF) |
| 187 | Night eating syndrome in class II–III obesity: metabolic and psychopathological features | 3.2 | 51 | Citations (PDF) |
| 188 | Self-induced vomiting in eating disorders: Associated features and treatment outcome | 3.8 | 30 | Citations (PDF) |
| 189 | Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet | 3.4 | 21 | Citations (PDF) |
| 190 | Metabolic Syndrome and Insulin Resistance in Subjects with Morbid Obesity | 2.4 | 31 | Citations (PDF) |
| 191 | Massive Weight Loss Without Surgery in a Super Obese Patient | 2.4 | 4 | Citations (PDF) |
| 192 | Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection | 2.1 | 22 | Citations (PDF) |
| 193 | Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? | 8.6 | 388 | Citations (PDF) |
| 194 | Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression | 2.6 | 259 | Citations (PDF) |
| 195 | Underweight eating disorder without over‐evaluation of shape and weight: Atypical anorexia nervosa? | 4.1 | 46 | Citations (PDF) |
| 196 | Retinol‐binding protein 4: A new marker of virus‐induced steatosis in patients infected with hepatitis c virus genotype 1 | 10.6 | 57 | Citations (PDF) |
| 197 | Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes | 10.6 | 649 | Citations (PDF) |
| 198 | Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database | 3.4 | 67 | Citations (PDF) |
| 199 | Personality dimensions and treatment drop-outs among eating disorder patients treated with cognitive behavior therapy | 3.3 | 22 | Citations (PDF) |
| 200 | Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa? | 3.8 | 39 | Citations (PDF) |
| 201 | Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study | 2.9 | 124 | Citations (PDF) |
| 202 | Compulsive exercise to control shape or weight in eating disorders: prevalence, associated features, and treatment outcome | 4.3 | 354 | Citations (PDF) |
| 203 | Nutritional treatment of chronic liver failure | 3.1 | 22 | Citations (PDF) |
| 204 | Vascular Risk in Young Women With Polycystic Ovary and Polycystic Ovary Syndrome | 1.4 | 47 | Citations (PDF) |
| 205 | Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection | 0.7 | 172 | Citations (PDF) |
| 206 | Hepatotoxicity of fast food? | 21.2 | 24 | Citations (PDF) |
| 207 | Which Treatment for Nonalcoholic Fatty Liver Disease? | 2.6 | 9 | Citations (PDF) |
| 208 | Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study | 0.7 | 282 | Citations (PDF) |
| 209 | Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database | 6.5 | 4 | Citations (PDF) |
| 210 | Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes | 3.4 | 16 | Citations (PDF) |
| 211 | Diabetes and liver disease: An ominous association | 3.4 | 114 | Citations (PDF) |
| 212 | Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question | 3.4 | 64 | Citations (PDF) |
| 213 | The effect of inpatient cognitive-behavioral therapy for eating disorders on temperament and character | 3.8 | 39 | Citations (PDF) |
| 214 | Metabolic Syndrome and NASH | 3.7 | 123 | Citations (PDF) |
| 215 | Essential hypertension and chronic viral hepatitis | 2.4 | 7 | Citations (PDF) |
| 216 | The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | 10.6 | 2,866 | Citations (PDF) |
| 217 | The Effect of Obesity Management on Body Image in Patients Seeking Treatment at Medical Centers | 4.2 | 40 | Citations (PDF) |
| 218 | Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage | 2.7 | 30 | Citations (PDF) |
| 219 | The treatment of hepatic encephalopathy | 3.0 | 66 | Citations (PDF) |
| 220 | NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes | 5.4 | 57 | Citations (PDF) |
| 221 | Psychological Distress in Morbid Obesity in Relation to Weight History | 2.4 | 58 | Citations (PDF) |
| 222 | Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study | 3.2 | 74 | Citations (PDF) |
| 223 | Construct Validity of the Short Form‐36 Health Survey and Its Relationship with BMI in Obese Outpatients | 4.2 | 47 | Citations (PDF) |
| 224 | Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting | 2.8 | 34 | Citations (PDF) |
| 225 | Complexity of attrition in the treatment of obesity: clues from a structured telephone interview | 3.2 | 100 | Citations (PDF) |
| 226 | Disease Management of the Metabolic Syndrome in a Community: Study Design and Process Analysis on Baseline Data | 2.1 | 10 | Citations (PDF) |
| 227 | Response to Letter | 0.7 | 3 | Citations (PDF) |
| 228 | Nonalcoholic fatty liver disease and the metabolic syndrome | 4.1 | 320 | Citations (PDF) |
| 229 | Branched-Chain Amino Acid Supplementation in Patients with Liver Diseases | 3.0 | 72 | Citations (PDF) |
| 230 | Update on branched-chain amino acid supplementation in liver diseases | 2.3 | 34 | Citations (PDF) |
| 231 | Update on nutritional supplementation with branched-chain amino acids | 3.2 | 39 | Citations (PDF) |
| 232 | A Positive Blood Alcohol Concentration Is the Main Predictor of Recurrent Motor Vehicle Crash | 1.1 | 27 | Citations (PDF) |
| 233 | Weight Loss Expectations in Obese Patients and Treatment Attrition: An Observational Multicenter Study | 4.2 | 260 | Citations (PDF) |
| 234 | Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study | 10.6 | 1,157 | Citations (PDF) |
| 235 | Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease | 10.6 | 575 | Citations (PDF) |
| 236 | Insulin resistance: A metabolic pathway to chronic liver disease | 10.6 | 793 | Citations (PDF) |
| 237 | Clinical Performance of NICE Recommendations versus NCWFNS Proposal in Patients with Mild Head Injury | 3.7 | 47 | Citations (PDF) |
| 238 | Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity | 4.2 | 374 | Citations (PDF) |
| 239 | Is liver disease a threat to patients with metabolic disorders? | 4.1 | 28 | Citations (PDF) |
| 240 | Psychological status and depression in patients with liver cirrhosis | 2.4 | 167 | Citations (PDF) |
| 241 | A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease | 0.7 | 649 | Citations (PDF) |
| 242 | A physical activity program to reinforce weight maintenance following a behavior program in overweight/obese subjects | 3.2 | 33 | Citations (PDF) |
| 243 | A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department | 2.1 | 10 | Citations (PDF) |
| 244 | Nutritional therapy in cirrhosis | 2.7 | 0 | Citations (PDF) |
| 245 | Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study | 3.2 | 59 | Citations (PDF) |
| 246 | Weight Loss Expectations in Obese Patients Seeking Treatment at Medical Centers | 4.2 | 68 | Citations (PDF) |
| 247 | Health-related quality of life in patients with thyroid disorders | 2.1 | 140 | Citations (PDF) |
| 248 | Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver | 10.6 | 403 | Citations (PDF) |
| 249 | Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure | 4.2 | 71 | Citations (PDF) |
| 250 | Non-alcoholic fatty liver and insulin resistance: a cause–effect relationship? | 2.4 | 79 | Citations (PDF) |
| 251 | Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment | 2.4 | 41 | Citations (PDF) |
| 252 | Non-alcoholic steatohepatitis in patients cared in metabolic units | 6.2 | 21 | Citations (PDF) |
| 253 | The metabolic syndrome in treatment-seeking obese persons | 9.5 | 50 | Citations (PDF) |
| 254 | Which type of observation for patients with high-risk mild head injury and negative computed tomography? | 1.3 | 16 | Citations (PDF) |
| 255 | Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment | 3.0 | 36 | Citations (PDF) |
| 256 | Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment | 3.0 | 32 | Citations (PDF) |
| 257 | Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome | 10.6 | 2,375 | Citations (PDF) |
| 258 | Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial | 1.0 | 589 | Citations (PDF) |
| 259 | Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance | 2.4 | 23 | Citations (PDF) |
| 260 | Reduced quality of life of patients with hepatocellular carcinoma | 2.4 | 51 | Citations (PDF) |
| 261 | Low Ghrelin Concentrations in Nonalcoholic Fatty Liver Disease Are Related to Insulin Resistance | 4.2 | 58 | Citations (PDF) |
| 262 | Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma | 1.0 | 1,354 | Citations (PDF) |
| 263 | Effects of long-term oral misoprostol administration on hepatic amino acid–nitrogen metabolism in patients with cirrhosis | 3.6 | 1 | Citations (PDF) |
| 264 | Homocysteine and psychological traits: a study in obesity | 2.9 | 17 | Citations (PDF) |
| 265 | Effects of cognitive–behavioural therapy on health-related quality of life in obese subjects with and without binge eating disorder | 3.2 | 47 | Citations (PDF) |
| 266 | Factors associated with poor health-related quality of life of patients with cirrhosis | 1.0 | 458 | Citations (PDF) |
| 267 | Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcohol steatohepatitis | 2.4 | 17 | Citations (PDF) |
| 268 | Metformin in non-alcoholic steatohepatitis | 52.8 | 663 | Citations (PDF) |
| 269 | Blood Alcohol Concentration and Management of Road Trauma Patients in the Emergency Department | 6.3 | 53 | Citations (PDF) |
| 270 | Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes | 3.4 | 536 | Citations (PDF) |
| 271 | Nutritional effects of oral zinc supplementation in cirrhosis | 2.8 | 35 | Citations (PDF) |
| 272 | Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis | 9.5 | 28 | Citations (PDF) |
| 273 | Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment | 2.4 | 45 | Citations (PDF) |
| 274 | Total and functional hepatic blood flow decrease in parallel with ageing | 1.8 | 152 | Citations (PDF) |
| 275 | Title is missing! | 2.3 | 8 | Citations (PDF) |
| 276 | Cardiovascular disease in cirrhosis A point-prevalence study in relation to glucose tolerance | 0.7 | 58 | Citations (PDF) |
| 277 | Association of nonalcoholic fatty liver disease with insulin resistance | 2.3 | 1,481 | Citations (PDF) |
| 278 | Effects of Systemic Prostaglandin E1 on Splanchnic and Peripheral Haemodynamics in Control Subjects and in Patients with Cirrhosis | 2.3 | 5 | Citations (PDF) |
| 279 | Effects of systemic prostaglandin e on hepatic amino acid-nitrogen metabolism in patients with cirrhosis | 10.6 | 11 | Citations (PDF) |
| 280 | Zinc supplementation improves glucose disposal in patients with cirrhosis | 9.5 | 65 | Citations (PDF) |
| 281 | Quantification of gluconeogenesis in cirrhosis: Response to glucagon | 1.0 | 59 | Citations (PDF) |
| 282 | Gender-dependent alterations in serum leptin in alcoholic cirrhosis | 1.0 | 146 | Citations (PDF) |
| 283 | LONG-TERM MANAGEMENT OF ALCOHOLIC LIVER DISEASE | 3.7 | 4 | Citations (PDF) |
| 284 | Glutathione kinetics in normal man and in patients with liver cirrhosis | 3.6 | 50 | Citations (PDF) |
| 285 | Overview of Randomized Clinical Trials of Oral Branched‐Chain Amino Acid Treatment in Chronic Hepatic Encephalopathy | 3.4 | 70 | Citations (PDF) |
| 286 | Transamination of methionine after loading in patients with cirrhosis | 3.6 | 9 | Citations (PDF) |
| 287 | Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation | 3.6 | 49 | Citations (PDF) |
| 288 | Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics | 3.6 | 10 | Citations (PDF) |
| 289 | Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis | 10.6 | 91 | Citations (PDF) |
| 290 | Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis | 10.6 | 38 | Citations (PDF) |
| 291 | The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death | 10.6 | 21 | Citations (PDF) |
| 292 | Thyroid volume in type 1 diabetes patients without overt thyroid disease | 2.4 | 12 | Citations (PDF) |
| 293 | Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis | 9.5 | 3 | Citations (PDF) |
| 294 | Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis | 3.6 | 61 | Citations (PDF) |
| 295 | Prognostic significance of diabetes in patients with cirrhosis | 10.6 | 165 | Citations (PDF) |
| 296 | Hepatic conversion of amino-nitrogen to urea in thyroid diseases. II. A study in hyperthyroid patients | 9.5 | 7 | Citations (PDF) |
| 297 | Kinetics of hepatic amino‐nitrogen conversion in ageing man | 0.0 | 24 | Citations (PDF) |
| 298 | Prognostic significance of diabetes in patients with cirrhosis*1 | 10.6 | 177 | Citations (PDF) |
| 299 | Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure | 10.6 | 19 | Citations (PDF) |
| 300 | Lactitol in treatment of chronic hepatic encephalopathy | 2.3 | 73 | Citations (PDF) |
| 301 | Thyroid involvement in chronic inflammatory rheumatological disorders | 2.4 | 41 | Citations (PDF) |
| 302 | Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon l-thyroxine therapy | 9.5 | 21 | Citations (PDF) |
| 303 | Prognostic significance of portal hemodynamics in patients with compensated cirrhosis | 3.6 | 91 | Citations (PDF) |
| 304 | Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis | 5.6 | 15 | Citations (PDF) |
| 305 | Polyamine plasma levels and liver regeneration following partial hepatic resection in man | 3.6 | 9 | Citations (PDF) |
| 306 | Defective methionine metabolism in cirrhosis: Relation to severity of liver disease | 10.6 | 59 | Citations (PDF) |
| 307 | Oral BCAA in the treatment of chronic hepatic encephalopathy | 3.6 | 6 | Citations (PDF) |
| 308 | Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus | 5.6 | 11 | Citations (PDF) |
| 309 | Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis | 2.3 | 88 | Citations (PDF) |
| 310 | Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method | 10.6 | 34 | Citations (PDF) |
| 311 | Intérêt de l'administration par voie orale d'acides aminés à chaîne ramifiée chez le cirrhotique encéphalopathe chronique | 0.2 | 5 | Citations (PDF) |
| 312 | Glucose disposal, β-cell secretion, and hepatic insulin extraction in cirrhosis: A minimal model assessment | 1.0 | 71 | Citations (PDF) |
| 313 | Mathematical model to analyse urea synthesis following alanine infusion in control subjects and in patients with liver cirrhosis | 2.4 | 1 | Citations (PDF) |
| 314 | Ultrasonographic follow-up of liver cirrhosis | 1.1 | 25 | Citations (PDF) |
| 315 | Synthesis of Urea after a Protein-rich Meal in Normal Man in Relation to Ageing | 1.8 | 20 | Citations (PDF) |
| 316 | Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy | 3.6 | 211 | Citations (PDF) |
| 317 | Carbohydrate metabolism in hepatocellular carcinoma: Where does the glucose go? | 10.6 | 8 | Citations (PDF) |
| 318 | Galactose elimination capacity and liver volume in aging man | 10.6 | 141 | Citations (PDF) |
| 319 | Insulin resistance in aged man: Relationship between impaired glucose tolerance and decreased insulin activity on branched-chain amino acids | 9.5 | 17 | Citations (PDF) |
| 320 | Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis | 3.6 | 55 | Citations (PDF) |
| 321 | Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis | 2.3 | 19 | Citations (PDF) |
| 322 | Portal venous flow in response to acute β-blocker and vasodilatatory treatment in patients with liver cirrhosis | 10.6 | 77 | Citations (PDF) |
| 323 | Echo-doppler measurement of splanchnic blood flow in control and cirrhotic subjects | 1.1 | 116 | Citations (PDF) |
| 324 | Degeneration of the corticospinal tract following portosystelnic shunt associated with spinal cord infarction | 1.4 | 19 | Citations (PDF) |
| 325 | Pancreatic β-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal | 9.5 | 24 | Citations (PDF) |
| 326 | The Euglycemic Clamp Technique in Patients with Liver Cirrhosis | 1.9 | 22 | Citations (PDF) |
| 327 | Insulin-dependent metabolism of branched-chain amino acids in obesity | 9.5 | 50 | Citations (PDF) |
| 328 | Plasma amino acid response to protein ingestion in patients with liver cirrhosis | 1.0 | 39 | Citations (PDF) |
| 329 | Effect of Euglycemic Insulin Infusion on Plasma Levels of Branched–Chain Amino Acids in Cirrhosis | 10.6 | 33 | Citations (PDF) |
| 330 | Ammonia-induced changes in pancreatic hormones and plasma amino acids in patients with liver cirrhosis | 2.3 | 17 | Citations (PDF) |
| 331 | Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion | 8.6 | 28 | Citations (PDF) |
| 332 | Branched-chain amino acids and alanine as indices of the metabolic control in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients | 8.6 | 41 | Citations (PDF) |
| 333 | Anticatabolic Effect of Branched–Chain Amino Acid–Enriched Solutions in Patients With Liver Cirrhosis | 10.6 | 89 | Citations (PDF) |
| 334 | Plasma Amino Acids as Markers of Liver Dysfunction in Cirrhotics | 1.8 | 11 | Citations (PDF) |
| 335 | Muscle protein breakdown in liver cirrhosis and the role of altered carbohydrate metabolism | 10.6 | 89 | Citations (PDF) |
| 336 | Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance | 2.3 | 62 | Citations (PDF) |
| 337 | Insulin and glucagon levels in liver cirrhosis | 2.3 | 81 | Citations (PDF) |
| 338 | Branched-chain amino acids for people with hepatic encephalopathy | 2.4 | 162 | Citations (PDF) |
| 339 | Management of non-alcoholic fatty liver disease | 0.2 | 137 | Citations (PDF) |
